In B cell malignancies, the loss or downregulation of surface antigen on tumor cells has been demonstrated to be a major mechanism of resistance against successful CD19-CAR T cell therapy.13 Recently, CAR T cell mediated trogocytosis has been reported to contribute to tumor antigen escape and CAR T cell dysfunction. Here, CD19 is linked to neoplasm.